Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

尽管季度业绩未达预期，但Recursion强调了其在推进人工智能驱动的药物发现平台和临床管线方面取得的进展。股价温和下跌表明，投资者虽然关注到近期收益未达预期，但对公司的长期发展潜力持谨慎乐观态度。

Leerink lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Market Perform rating on the shares after ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago. These ...

英为财情Investing.com - Recursion Pharmaceuticals (NASDAQ: RXRX)星期五发布了第四季度的财报，数据显示，公司营收逊于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.53，总营收为$4.55M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$13.4M，每股收益为$- ...

TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report) today. The company’s shares ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.

Full Year 2024 Results Key Financial Results Revenue: US$58.8m (up 32% ...

We recently compiled a list of the Last Week's Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...